Thr235
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr235  -  C/EBP-beta (human)

Site Information
SsssPPGtPSPADAK   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 447878
Available spectra:  3 CST

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 13 , 14 , 15 , 16 , 20 ) , mutation of modification site ( 24 , 26 ) , phospho-antibody ( 19 , 21 , 22 , 23 , 24 , 25 , 26 ) , western blotting ( 19 , 21 , 22 , 23 , 24 , 26 )
Disease tissue studied:
breast cancer ( 2 ) , liver cancer ( 22 ) , lung cancer ( 1 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 19 ) , non-small cell lung cancer ( 5 , 6 , 7 , 9 , 10 , 11 , 13 , 14 , 15 , 16 ) , non-small cell lung adenocarcinoma ( 1 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 15 ) , non-small cell large cell lung carcinoma ( 6 , 9 ) , non-small cell squamous cell lung carcinoma ( 8 ) , small-cell lung cancer ( 3 , 4 ) , lymphoma ( 21 )
Relevant cell line - cell type - tissue:
'epithelial, lung' ( 25 ) , 293 (epithelial) ( 20 ) , 293T (epithelial) ( 26 ) , 3T3 (fibroblast) [SHP-2 (mouse), homozygous knockout] ( 26 ) , A549 (pulmonary) ( 5 , 16 , 19 ) , Cal-12T (pulmonary) ( 11 ) , Calu-3 (pulmonary) ( 7 ) , DMS153 (pulmonary) ( 10 ) , DMS53 (pulmonary) ( 4 ) , DMS79 (pulmonary) ( 3 ) , HCC15 (pulmonary) ( 8 ) , HCC44 (pulmonary) ( 11 ) , HCC78 (pulmonary) ( 9 ) , HCC827 (pulmonary) ( 7 ) , HepG2 (hepatic) ( 22 ) , HMLER ('stem, breast cancer') ( 2 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 2 ) , HSF (fibroblast) ( 24 ) , LOU-NH91 (squamous) ( 8 ) , lung ( 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 ) , monocyte ( 23 ) , NCI-H128 (pulmonary) ( 3 ) , NCI-H1299 (pulmonary) ( 6 ) , NCI-H1355 (pulmonary) ( 5 ) , NCI-H1417 (pulmonary) ( 3 ) , NCI-H1437 (pulmonary) ( 10 , 11 ) , NCI-H1650 (pulmonary) ( 7 ) , NCI-H1666 (pulmonary) ( 11 ) , NCI-H1703 (squamous) ( 8 ) , NCI-H1734 (pulmonary) ( 6 ) , NCI-H1781 (pulmonary) ( 9 ) , NCI-H1792 (pulmonary) ( 5 ) , NCI-H1944 (pulmonary) ( 6 ) , NCI-H1975 (pulmonary) ( 7 ) , NCI-H2073 (pulmonary) ( 8 , 10 ) , NCI-H209 (pulmonary) ( 3 , 10 ) , NCI-H2106 (pulmonary) ( 7 ) , NCI-H2228 (pulmonary) ( 9 , 15 ) , NCI-H23 (pulmonary) ( 5 ) , NCI-H2342 (pulmonary) ( 8 ) , NCI-H2405 (pulmonary) ( 11 ) , NCI-H3122 (pulmonary) ( 9 , 13 , 14 ) , NCI-H358 (pulmonary) ( 6 ) , NCI-H441 (pulmonary) ( 5 , 25 ) , NCI-H446 (pulmonary) ( 4 ) , NCI-H460 (pulmonary) ( 6 ) , NCI-H524 (pulmonary) ( 3 ) , NCI-H526 (pulmonary) ( 4 ) , NCI-H661 (pulmonary) ( 9 ) , NCI-H69 (pulmonary) ( 4 ) , NCI-H82 (pulmonary) ( 4 ) , NCI-H838 (pulmonary) ( 10 ) , PC9 (pulmonary) ( 1 ) , PC9-IR (pulmonary) ( 1 ) , U-937 (myeloid) ( 21 )

Upstream Regulation
Regulatory protein:
Akt1 (human) ( 18 ) , MEKK1 (human) ( 24 ) , mTOR (human) ( 18 )
Putative in vivo kinases:
ERK1 (human) ( 19 , 26 ) , ERK2 (human) ( 19 ) , HIPK2 (human) ( 12 )
Treatments:
amino_acid_starvation ( 22 ) , culturing_of_cells ( 23 ) , GH ( 26 ) , glucocorticoid ( 25 ) , IL-1b ( 19 ) , LY294002 ( 23 ) , PD98059 ( 22 ) , PGE2 ( 24 ) , phorbol_ester ( 21 ) , U0126 ( 18 , 19 , 23 , 26 )

Downstream Regulation
Effects of modification on C/EBP-beta:
activity, induced ( 19 , 25 ) , molecular association, regulation ( 21 )
Effects of modification on biological processes:
cell differentiation, altered ( 23 ) , transcription, altered ( 19 ) , transcription, induced ( 25 , 26 )
Inhibit interaction with:
EHMT2 iso4 (human) ( 21 )

References 

1

Tsai CF, et al. (2015) Large-scale determination of absolute phosphorylation stoichiometries in human cells by motif-targeting quantitative proteomics. Nat Commun 6, 6622
25814448   Curated Info

2

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

3

Rikova K, Hall B (2013) CST Curation Set: 20734, 21161, 30112, 30153, 30154; Year: 2013; Biosample/Treatment: cell line, H1417, DMS79, H128, H209, H524; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

4

Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

5

Rikova K, Hall B (2013) CST Curation Set: 20736, 21163, 30158, 30159, 30160; Year: 2013; Biosample/Treatment: cell line, A549, H1355, H23, H441, H1792; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

6

Rikova K, Hall B (2013) CST Curation Set: 20737, 21164, 30161, 30162, 30163; Year: 2013; Biosample/Treatment: cell line, H1299, H1944, H358, H1734, H460; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

7

Rikova K, Hall B (2013) CST Curation Set: 20738, 21165, 30164, 30165, 30166; Year: 2013; Biosample/Treatment: cell line, H1650, HCC827, H1975, Calu-3, H2106; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

8

Rikova K, Hall B (2013) CST Curation Set: 20739, 21166, 30167, 30168, 30169; Year: 2013; Biosample/Treatment: cell line, H2342, H2073, Lou-NH91, HCC15, H1703; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

9

Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

10

Rikova K, Hall B (2013) CST Curation Set: 20742, 21169, 30176, 30177, 30178; Year: 2013; Biosample/Treatment: cell line, H838, DMS153, H2073, H209, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

11

Rikova K, Hall B (2013) CST Curation Set: 20741, 21168, 30173, 30174, 30175; Year: 2013; Biosample/Treatment: cell line, H1666, CAL-12T, H2405, HCC44, H1437; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P
Curated Info

12

Steinmann S, et al. (2013) Interaction and Cooperation of the CCAAT-box Enhancer-binding Protein β (C/EBPβ) with the Homeodomain-interacting Protein Kinase 2 (Hipk2). J Biol Chem 288, 22257-69
23782693   Curated Info

13

Rikova K (2013) CST Curation Set: 18503; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pSQ, p[ST]QG Antibodies Used to Purify Peptides prior to LCMS: Phospho-ATM/ATR Substrate (S*Q) (D23H2/D69H5) Rabbit mAb Cat#: 9607 Phospho-(Ser/Thr) ATM/ATR Substrate (S*/T*QG) (P-S/T2-100) Rabbit mAb Cat#: 6966
Curated Info

14

Rikova K (2013) CST Curation Set: 18459; Year: 2013; Biosample/Treatment: cell line, H3122/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

15

Rikova K (2013) CST Curation Set: 18458; Year: 2013; Biosample/Treatment: cell line, H2228/crizotinib, geldanamycin; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST](AGC)
Curated Info

16

Rikova K (2012) CST Curation Set: 16144; Year: 2012; Biosample/Treatment: cell line, A549/iressa, gleevec, crizotinib; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]
Curated Info

17

Atwood AA, Jerrell R, Sealy L (2011) Negative regulation of C/EBPbeta1 by sumoylation in breast cancer cells. PLoS One 6, e25205
21980398   Curated Info

18

Anastasov N, et al. (2010) C/EBPbeta expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica 95, 760-7
20015877   Curated Info

19

Armstrong DA, Phelps LN, Vincenti MP (2009) CCAAT enhancer binding protein-beta regulates matrix metalloproteinase-1 expression in interleukin-1beta-stimulated A549 lung carcinoma cells. Mol Cancer Res 7, 1517-24
19723873   Curated Info

20

Gauci S, et al. (2009) Lys-N and trypsin cover complementary parts of the phosphoproteome in a refined SCX-based approach. Anal Chem 81, 4493-501
19413330   Curated Info

21

Pless O, et al. (2008) G9a-mediated lysine methylation alters the function of CCAAT/enhancer-binding protein-beta. J Biol Chem 283, 26357-63
18647749   Curated Info

22

Thiaville MM, et al. (2008) Deprivation of protein or amino acid induces C/EBPbeta synthesis and binding to amino acid response elements, but its action is not an absolute requirement for enhanced transcription. Biochem J 410, 473-84
18052938   Curated Info

23

Pham TH, et al. (2007) CCAAT enhancer-binding protein beta regulates constitutive gene expression during late stages of monocyte to macrophage differentiation. J Biol Chem 282, 21924-33
17540774   Curated Info

24

Faour WH, et al. (2006) Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts. Role in suppression of c/EBP/NF-kappaB-mediated MEKK1-induced MMP-1 expression. J Biol Chem 281, 19849-60
16714289   Curated Info

25

Berg T, et al. (2005) Glucocorticoids increase C/EBPbeta activity in the lung epithelium via phosphorylation. Biochem Biophys Res Commun 334, 638-45
16009338   Curated Info

26

Piwien-Pilipuk G, MacDougald O, Schwartz J (2002) Dual regulation of phosphorylation and dephosphorylation of C/EBPbeta modulate its transcriptional activation and DNA binding in response to growth hormone. J Biol Chem 277, 44557-65
12213825   Curated Info